Pharmacodynamics and pharmacokinetics
Pharmacodynamics
Antimicrobial agent for external use, sulfanilamide . When applied to a burn surface, silver sulfadiazine begins to disintegrate, slowly releasing sulfonamide and silver , which inhibits the growth and reproduction of infectious cells.
Dermazin has a wide spectrum of antibacterial activity, including all types of microorganisms that cause infection of wounds, including burn wounds (Escherichia coli, Pseudomonas aeruginosa, the genus Staphylococcus, Proteus, Klebsiella, Streptococcus, Enterobacter), as well as yeast fungi (Candida albicans), and a number herpevirus strains.
Able to penetrate exudate and necrotic tissue.
Pharmacokinetics
During long-term treatment of burn wounds over a large surface, the drug is absorbed into the bloodstream. Serum sulfonamide concentrations
sulfadiazine entering the blood is excreted unchanged in the urine; the half-life is 10 hours.
Pharmacological properties of the drug Dermazin
Chemotherapeutic agent with antimicrobial action for topical use. Used to prevent and treat infections in burns. In the wound, silver sulfadiazine dissociates, slowly and uniformly releasing silver ions. The silver ion binds to the DNA of bacteria, which leads to the suppression of their growth and reproduction and does not affect the cells of the skin and subcutaneous tissues. Dermazin has a broad antibacterial spectrum; it is active against almost all microorganisms that can infect burn wounds. Dermazin penetrates well into foci of necrosis and exudate. This property of the drug is especially important, since systemically used antibiotics do not act on microorganisms in the area of burn necrosis, which is excluded from the blood circulation. During long-term treatment of extensive burn wounds, the drug may be absorbed. Serum concentrations of sulfonamide are proportional to the area of the burn wound surface and the amount of cream applied. After application of 500–1000 g of 1% silver sulfadiazine cream (equivalent to 5–10 g of silver sulfadiazine), the serum sulfadiazine level is 2–5 mg/L and the urine level is 50–100 mg/L, respectively. Argyria does not develop due to systemic silver absorption.
Side effects
- Local reactions: burning , itching .
- Hematopoietic reactions: temporary leukopenia and neutropenia.
- There are rare reports of erythema multiforme, skin necrosis, pigmentation changes and interstitial nephritis.
- In even more rare cases, sulfonamide adverse reactions are detected: agranulocytosis, aplastic anemia, leukopenia, thrombocytopenia, hepatocellular necrosis, hemolytic anemia, exfoliative dermatitis, hepatitis, dyspepsia, neurological reactions, toxic nephrosis.
Side effects of the drug Dermazin
Local: skin irritation, burning sensation, skin hypersensitivity reactions (hyperemia, itching, photosensitivity), rarely - discoloration and necrosis of the skin. Systemic: with long-term treatment of burn wounds on a large surface of the skin, the level of sulfonamide concentration in the blood serum may approach the level characteristic of systemic use of the drug. In this regard, reactions associated with the use of sulfonamides are possible: nausea, vomiting, diarrhea, glossitis, joint pain, liver dysfunction, leukopenia, thrombocytopenia, eosinophilia.
Instructions for use (Method and dosage)
The instructions for the ointment allow it to be used with or without bandages. This product is intended for use on the skin only.
Cream Dermazin, instructions for use
After surgical treatment of the burn, the cream is applied in a layer up to 4 mm thick once or twice a day.
Treatment is continued until the burn or wound is completely healed. The method of application is the same for the treatment of trophic ulcers and burns. Bandages must be changed daily.
Use of the drug Dermazin
The appropriate treatment regimen is prescribed immediately after assessing the size and depth of the wound surface. After cleansing the surface of the burn, Dermazin is applied to the burned area (or to a sterile gauze pad that is applied to the burn surface) in a layer of 2–4 mm. The cream is applied with a sterile spatula or by hand (wearing a sterile glove), usually once a day; in severe cases, the cream is applied twice a day. Before each re-application, you need to wash off the remnants of the previous layer of cream and wound exudate with water or an antiseptic solution. You can apply a bandage. The method of administration and dose of the drug do not depend on the treatment or prevention, or on the age of the patient. The cream does not leave stains on clothes and bed linen.
special instructions
It is recommended to prescribe the drug with caution to persons with hypersensitivity to sulfonamides (possible cross-reactions), glucose-6-phosphate dehydrogenase deficiency (possible hemolysis ), impaired liver and kidney function (possible accumulation of the drug), and porphyria .
With long-term use of Dermazin over a large surface, blood counts should be monitored due to the possible occurrence of thrombocytopenia, leukopenia or eosinophilia.
Do not allow Dermazin to get into your eyes.
Special instructions for the use of the drug Dermazin
Avoid getting the drug into your eyes. In case of hypersensitivity to sulfonamides, caution must be exercised due to the possible development of allergic reactions in patients with congenital deficiency of glucose-6-phosphate dehydrogenase, impaired liver and kidney function. With long-term use of the drug, it is necessary to monitor the blood count (since the development of leukopenia, thrombocytopenia, eosinophilia), the concentration of sulfadiazine in the blood serum, liver and kidney function, as well as the possible appearance of sulfadiazine in the urine. As with the use of other local antimicrobial agents, superinfection may develop as a result of treatment with silver sulfadiazine. Very rarely, an increase in body temperature is possible, which is associated with unwanted side effects. Use during pregnancy and lactation. Safety of use has not been established. Dermazin should not be used during pregnancy, especially before childbirth, and during breastfeeding, unless the potential benefit to the mother outweighs the possible risk to the fetus/child. Impact on the ability to drive vehicles or machinery . No data.
Dermazin price, where to buy
The price of Dermazin ointment 50 grams in Russia ranges from 202-223 rubles, and in Ukraine the price of this form of release is on average 118 hryvnia.
- Online pharmacies in RussiaRussia
- Online pharmacies in UkraineUkraine
- Online pharmacies in KazakhstanKazakhstan
ZdravCity
- Dermazin cream 1% 50g Lek dd/Salutas Pharma GmbH
RUB 272 order
Pharmacy Dialogue
- Dermazin cream tube 50g Salutas Pharma GmbH
RUB 272 order
show more
Pharmacy24
- Dermazin 1% 50 g cream Salutas Pharma GmbH, Nimechchina
215 UAH.order
PaniPharmacy
- Dermazin cream Dermazin cream 1% 50g Slovenia, Lek
215 UAH order
show more
Dermazin, 1 piece, 50 g, 1%, cream for external use
Avoid getting the drug into your eyes. Dermazin cream should be used with caution in patients with hypersensitivity to sulfonamides (due to the possible occurrence of allergic reactions); with congenital deficiency of glucose-6-phosphate dehydrogenase (in the treatment of minor superficial burns); with impaired renal or liver function (cumulation may occur; for such patients, monitoring of the level of sulfonamide in the blood plasma is necessary). Not used in patients with porphyria. Dangerous skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported during treatment with sulfadiazine. The greatest risk of such reactions occurs in the first weeks of treatment. At the first manifestations of hypersensitivity (progressive skin rash, often with blisters and damage to the mucous membrane), use of the drug should be discontinued. Only for minor superficial burns can the cream be used independently. Patients with deeper burns should always consult a physician before starting treatment. Burns affecting 2% or more of the body's surface area (approximately 1 palm of the patient's hand corresponds to 1% of the patient's body surface area), as well as burns affecting the eyes, ears, face, arms, legs, and/or perineum, require medical evaluation. Consultation with a physician is necessary for skin wounds containing foreign materials that cannot be removed; with deep puncture wounds; animal bites; for wounds with significant redness, sudden development of edema and wounds accompanied by fever. If treatment involves long-term use of Dermazin cream over large areas of skin, monitoring of blood counts is necessary, since leukopenia, thrombocytopenia and eosinophilia may occur. When treating massive wounds, plasma concentrations of sulfadiazine can reach therapeutic levels. Systemic side effects of sulfonamides may develop. Therefore, it is recommended to monitor the concentration of sulfadiazine in the blood plasma, kidney function, and also examine the urine for the occurrence of crystalluria. As with other local antimicrobial agents, superinfection may develop during treatment. Very rarely, an increase in body temperature is possible, which is associated with unwanted side effects. The excipients methyl parahydroxybenzoate and propyl parahydroxybenzoate can cause allergic reactions, including delayed ones, and in some cases bronchospasm. Dermazin contains peanut oil. Patients with hypersensitivity to peanuts or soy should not use this drug. Propylene glycol, which is part of the drug, may cause skin irritation. Cetyl alcohol may also cause local skin reactions (eg contact dermatitis). Children. Due to the risk of kernicterus, silver sulfadiazine should not be used in premature infants, newborns and children under 3 months of age. Since the effectiveness and safety of the drug in children over 3 months of age have not been determined, it is recommended to prescribe the drug to patients in this age category after consultation with a doctor. The ability to influence reaction speed when driving vehicles or working with other mechanisms. There is no data regarding negative effects.
Dermazin, 1%, cream for external use, 250 g, 1 pc.
Avoid getting the drug into your eyes. Dermazin cream should be used with caution in patients with hypersensitivity to sulfonamides (due to the possible occurrence of allergic reactions); with congenital deficiency of glucose-6-phosphate dehydrogenase (in the treatment of minor superficial burns); with impaired renal or liver function (cumulation may occur; for such patients, monitoring of the level of sulfonamide in the blood plasma is necessary). Not used in patients with porphyria. Dangerous skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported during treatment with sulfadiazine. The greatest risk of such reactions occurs in the first weeks of treatment. At the first manifestations of hypersensitivity (progressive skin rash, often with blisters and damage to the mucous membrane), use of the drug should be discontinued. Only for minor superficial burns can the cream be used independently. Patients with deeper burns should always consult a physician before starting treatment. Burns affecting 2% or more of the body's surface area (approximately 1 palm of the patient's hand corresponds to 1% of the patient's body surface area), as well as burns affecting the eyes, ears, face, arms, legs, and/or perineum, require medical evaluation. Consultation with a physician is necessary for skin wounds containing foreign materials that cannot be removed; with deep puncture wounds; animal bites; for wounds with significant redness, sudden development of edema and wounds accompanied by fever. If treatment involves long-term use of Dermazin cream over large areas of skin, monitoring of blood counts is necessary, since leukopenia, thrombocytopenia and eosinophilia may occur. When treating massive wounds, plasma concentrations of sulfadiazine can reach therapeutic levels. Systemic side effects of sulfonamides may develop. Therefore, it is recommended to monitor the concentration of sulfadiazine in the blood plasma, kidney function, and also examine the urine for the occurrence of crystalluria. As with other local antimicrobial agents, superinfection may develop during treatment. Very rarely, an increase in body temperature is possible, which is associated with unwanted side effects. The excipients methyl parahydroxybenzoate and propyl parahydroxybenzoate can cause allergic reactions, including delayed ones, and in some cases bronchospasm. Dermazin contains peanut oil. Patients with hypersensitivity to peanuts or soy should not use this drug. Propylene glycol, which is part of the drug, may cause skin irritation. Cetyl alcohol may also cause local skin reactions (eg contact dermatitis). Children. Due to the risk of kernicterus, silver sulfadiazine should not be used in premature infants, newborns and children under 3 months of age. Since the effectiveness and safety of the drug in children over 3 months of age have not been determined, it is recommended to prescribe the drug to patients in this age category after consultation with a doctor. The ability to influence reaction speed when driving vehicles or working with other mechanisms. There is no data regarding negative effects.
Directions for use and doses
Externally.
After surgical treatment of the wound, Dermazin® cream is applied in a layer 2–4 mm thick to the damaged surface 1–2 times a day until the wound surface is completely healed. Before each re-application of the cream, it is necessary to remove the previous layer of the drug with water or antiseptic drugs.
Dermazin® can be used with or without sterile dressings; dressings should be changed daily.
There are no pain effects when changing dressings.
Treatment with Dermazin® cream is continued until the wound surface is completely healed.
The method of using the cream is the same for the treatment of burns and trophic ulcers.
